Clinical Trial Results:
A Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysine For Inhalation in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa (AIR-CF4)
Summary
|
|
EudraCT number |
2015-000395-97 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
19 Jun 2009
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
22 Mar 2016
|
First version publication date |
05 Aug 2015
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
GS-US-205-0117
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT00712166 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Gilead Sciences, Inc.
|
||
Sponsor organisation address |
333 Lakeside Drive, Foster City, CA, United States, 94404
|
||
Public contact |
Clinical Trial Mailbox, Gilead Sciences International Ltd, ClinicalTrialDisclosures@gilead.com
|
||
Scientific contact |
Clinical Trial Mailbox, Gilead Sciences International Ltd, ClinicalTrialDisclosures@gilead.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
19 Jun 2009
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
19 Jun 2009
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The purpose of this study was to evaluate the safety and efficacy of a 28-day course of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF), mild lung disease (forced expiratory volume in 1 second [FEV1] >75% predicted), and Pseudomonas aeruginosa (PA) infection.
|
||
Protection of trial subjects |
The protocol and consent/assent forms were submitted by each investigator to a duly constituted Independent Ethics Committee (IEC) or Institutional Review Board (IRB) for review and approval before study initiation. All revisions to the consent/assent forms (if applicable) after initial IEC/IRB approval were submitted by the investigator to the IEC/IRB for review and approval before implementation in accordance with regulatory requirements.
This study was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Conference on Harmonization guideline for Good Clinical Practice (ICH GCP) and the original principles embodied in the Declaration of Helsinki.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
16 Jun 2008
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Canada: 2
|
||
Country: Number of subjects enrolled |
Australia: 10
|
||
Country: Number of subjects enrolled |
United States: 145
|
||
Worldwide total number of subjects |
157
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
22
|
||
Adolescents (12-17 years) |
67
|
||
Adults (18-64 years) |
68
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
Participants were randomized at 39 sites in total: 34 in the United States, 1 in Canada, and 4 in Australia. Date of first screening was 16 June 2008, and date of last participant observation was 19 June 2009. | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
Planned trial size was approximately 140 participants randomized in 1:1 ratio to aztreonam for inhalation solution (AZLI) three times daily (TID) or placebo TID. 160 participants were randomized, 157 received blinded study drug (76 AZLI; 81 placebo). One participant who was randomized and treated with study drug discontinued the study. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Overall study (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Investigator, Monitor, Subject, Data analyst | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Placebo | |||||||||||||||
Arm description |
Participants received placebo to match AZLI self administered 3 times daily (TID) for the duration of the study. | |||||||||||||||
Arm type |
Placebo | |||||||||||||||
Investigational medicinal product name |
Placebo to match AZLI
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Nebuliser solution
|
|||||||||||||||
Routes of administration |
Inhalation use
|
|||||||||||||||
Dosage and administration details |
Placebo to match AZLI (5 mg/mL lactose when reconstituted in diluent [0.17% saline]; sterile, pH 4.2 to 7.5, and osmolality 200 to 400 mOsmol/kg) administered using an eFlow nebulizer
|
|||||||||||||||
Arm title
|
AZLI | |||||||||||||||
Arm description |
Participants received AZLI self administered 3 times daily for the duration of the study. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Aztreonam for inhalation solution
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
AZLI, Cayston®
|
|||||||||||||||
Pharmaceutical forms |
Nebuliser solution
|
|||||||||||||||
Routes of administration |
Inhalation use
|
|||||||||||||||
Dosage and administration details |
AZLI (75 mg aztreonam and 52.5 mg lysine monohydrate reconstituted in diluent [0.17% saline] with a pH of 4.4 to 5.4, and osmolality 350 to 550 mOsmol/kg) administered using an eFlow nebulizer
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received placebo to match AZLI self administered 3 times daily (TID) for the duration of the study. | ||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
AZLI
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received AZLI self administered 3 times daily for the duration of the study. | ||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Placebo
|
||
Reporting group description |
Participants received placebo to match AZLI self administered 3 times daily (TID) for the duration of the study. | ||
Reporting group title |
AZLI
|
||
Reporting group description |
Participants received AZLI self administered 3 times daily for the duration of the study. |
|
|||||||||||||
End point title |
Change from baseline in Cystic Fibrosis Questionnaire – Revised (CFQ-R) respiratory symptoms scale (RSS) score at Day 28 | ||||||||||||
End point description |
The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for children and adults with CF. The CFQ-R contains both general and CF-specific scales. The CFQ-R was administered at Days 0, 14, 28, and 42. The endpoint was change in respiratory symptoms (e.g., coughing, congestion, wheezing) from Day 0 (baseline), assessed with the CFQ-R RSS (score range: 0-100; higher scores indicating fewer symptoms, higher health-related quality of life, or better functioning). Baseline CFQ-R RSS and age group (<18 vs. >=18 years) were included as covariates in the analysis. Analysis on intent-to-treat (ITT) population (received at least part of 1 dose of AZLI/placebo). Missing baseline data not imputed. Missing post-baseline data imputed with worst-case value for participants who withdrew due to an adverse event (AE)/study drug intolerance. Imputation for other missing data was last observation carried forward (LOCF).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Day 0 to Day 28
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Difference in change from baseline | ||||||||||||
Statistical analysis description |
Null hypothesis was there was no difference between 75 mg AZLI TID and placebo treatment groups in change from baseline in CFQ-R RSS score at Day 28. At the 5% significance level (i.e., α = 0.05) using a two-sided significance test, a sample size of 70 participants per treatment group provided at least 90% power to detect a 10 point difference between groups in the mean change from baseline at Day 28 in the CFQ-R RSS score, assuming a common standard deviation (SD) of 17.5.
|
||||||||||||
Comparison groups |
Placebo v AZLI
|
||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.433 [1] | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
1.8
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-2.83 | ||||||||||||
upper limit |
6.44 | ||||||||||||
Notes [1] - The primary endpoint analysis was based on a two-sided test with an 0.05 a priori threshold for statistical significance. A gate-keeper approach was established a priori to control the type 1 error rate, however, the primary endpoint was not met. |
|
|||||||||||||
End point title |
Change from baseline in CFQ-R RSS score at Day 14 | ||||||||||||
End point description |
The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for children and adults with CF. The CFQ-R contains both general and CF-specific scales. The CFQ-R was administered at Days 0, 14, 28, and 42. The endpoint was change in respiratory symptoms (e.g., coughing, congestion, wheezing) from Day 0 (baseline), assessed with the CFQ-R RSS (score range: 0-100; higher scores indicating fewer symptoms, higher health-related quality of life, or better functioning). Baseline CFQ-R RSS and age group (<18 vs. >=18 years) were included as covariates in the analysis. Analysis based on ITT population (all participants receiving at least part of one dose of AZLI or placebo). Missing baseline data were not imputed. Missing post-baseline data were imputed using worst-case value for participants who withdrew due to an AE or study drug intolerance. For all other missing data, LOCF imputation method was used.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 0 to Day 14
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Difference in change from baseline | ||||||||||||
Statistical analysis description |
Null hypothesis was there was no difference between 75 mg AZLI TID and placebo treatment groups in change from baseline in the CFQ-R RSS score at Day 14.
|
||||||||||||
Comparison groups |
Placebo v AZLI
|
||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other [2] | ||||||||||||
P-value |
= 0.133 [3] | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
3.37
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-1.04 | ||||||||||||
upper limit |
7.78 | ||||||||||||
Notes [2] - Intergroup analysis of change from baseline in RSS score. [3] - No adjustments were made for multiple comparisons. |
|
|||||||||||||
End point title |
Change from baseline in CFQ-R RSS score at Day 42 | ||||||||||||
End point description |
The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for children and adults with CF. The CFQ-R contains both general and CF-specific scales. The CFQ-R was administered at Days 0, 14, 28, and 42. The endpoint was change in respiratory symptoms (e.g., coughing, congestion, wheezing) from Day 0 (baseline), assessed with the CFQ-R RSS (score range: 0-100; higher scores indicating fewer symptoms, higher health-related quality of life, or better functioning). Baseline CFQ-R RSS and age group (<18 vs. >=18 years) were included as covariates in the analysis. Analysis based on ITT population (all participants receiving at least part of one dose of AZLI or placebo). Missing baseline data were not imputed. Missing post-baseline data were imputed using worst-case value for participants who withdrew due to an AE or study drug intolerance. For all other missing data, LOCF imputation method was used.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 0 to Day 42
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Difference in change from baseline | ||||||||||||
Statistical analysis description |
Null hypothesis was there was no difference between 75 mg AZLI TID and placebo treatment groups in change from baseline in the CFQ-R RSS score at Day 42.
|
||||||||||||
Comparison groups |
Placebo v AZLI
|
||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other [4] | ||||||||||||
P-value |
= 0.965 [5] | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
0.1
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-4.56 | ||||||||||||
upper limit |
4.76 | ||||||||||||
Notes [4] - Intergroup analysis of change from baseline in RSS score. [5] - No adjustments were made for multiple comparisons. |
|
|||||||||||||
End point title |
Change From Baseline in CFQ-R Physical Functioning Domain Score | ||||||||||||
End point description |
The CFQ-R contains both general and CF-specific scales. The CFQ-R was administered at Days 0 (baseline), 14,
28, and 42 (the last study visit). The endpoint was change from baseline in the physical functioning domain (e.g., ability to walk and engage in physical activities) of the CFQ-R at Day 28 (range of scores: 0-100; higher scores indicating fewer symptoms, higher health-related quality of life, or better functioning). Baseline CFQ-R physical functioning domain score and age group (<18 vs. >=18 years) were included as covariates in the analysis. Analysis based on ITT population (all participants receiving at least part of one dose of AZLI or placebo). Missing baseline data were not imputed. Missing post-baseline data were imputed using worst-case value for participants who withdrew due to an AE or study drug intolerance. For all other missing data, LOCF imputation method was used.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 0 to Day 28
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Difference in change from baseline | ||||||||||||
Statistical analysis description |
Null hypothesis was there was no difference between 75 mg AZLI TID and placebo treatment groups in change from baseline in the CFQ-R physical functioning domain score at Day 28.
|
||||||||||||
Comparison groups |
Placebo v AZLI
|
||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other [6] | ||||||||||||
P-value |
= 0.256 [7] | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
2.47
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-1.81 | ||||||||||||
upper limit |
6.76 | ||||||||||||
Notes [6] - Intergroup analysis of change from baseline in physical domain score. [7] - No adjustments were made for multiple comparisons. |
|
||||||||||
End point title |
Number of participants using additional (nonprotocol-specified) antipseudomonal antibiotics during study | |||||||||
End point description |
The number of participants requiring additional antipseudomonal antibiotics (oral, intravenous [IV], or by inhalation), the time to use of these antibiotics, and the reasons for use was recorded. A binary variable was defined to indicate whether the participants needed any antipseudomonal antibiotics that were non-study drug via the oral, IV, or inhalation route between Day 0 (Baseline Visit) and Day 42 (Visit 5). Fisher's Exact Test was implemented on the intent-to-treat (ITT) and per protocol analysis sets to detect treatment effects on need for additional antipseudomonal antibiotics. Analysis based on ITT population (all participants who received at least part of one dose of AZLI or placebo). No imputation methods were used for the analysis.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Day 0 to Day 42
|
|||||||||
|
||||||||||
Statistical analysis title |
Difference in antibiotic use | |||||||||
Statistical analysis description |
Null hypothesis was there was no difference between 75 mg AZLI TID and placebo treatment groups in number of participants using additional (nonprotocol-specified) antipseudomonal antibiotics during study.
|
|||||||||
Comparison groups |
Placebo v AZLI
|
|||||||||
Number of subjects included in analysis |
157
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
other [8] | |||||||||
P-value |
> 0.999 [9] | |||||||||
Method |
Fisher exact | |||||||||
Confidence interval |
||||||||||
Notes [8] - Intergroup analysis of nonprotocol-specified antipseudomonal antibiotic use. [9] - No adjustments were made for multiple comparisons. |
|
||||||||||
End point title |
Number of participants hospitalized during study | |||||||||
End point description |
Hospitalization was defined as any hospital admission lasting for more than 1 calendar day that had been recorded as a serious adverse event (SAE) on the electronic case report form (eCRF). Binary variables were defined to indicate whether participants experienced any hospitalization. Number of hospitalizations was summarized by treatment group. Analysis based on ITT population (all participants who received at least part of one dose of AZLI or placebo). No imputation methods were used for the analysis.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Day 0 to Day 42
|
|||||||||
|
||||||||||
Statistical analysis title |
Difference in hospitalization rate | |||||||||
Statistical analysis description |
Null hypothesis was there was no difference between 75 mg AZLI TID and placebo treatment groups in proportion of participants hospitalized.
|
|||||||||
Comparison groups |
Placebo v AZLI
|
|||||||||
Number of subjects included in analysis |
157
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
other [10] | |||||||||
P-value |
= 0.122 [11] | |||||||||
Method |
Fisher exact | |||||||||
Confidence interval |
||||||||||
Notes [10] - Intergroup analysis of hospitalization rate. [11] - No adjustments were made for multiple comparisons. |
|
|||||||||||||
End point title |
Change from baseline in Log10 Pseudomonas aeruginosa (PA) colony forming units (CFUs) in sputum at Day 28 | ||||||||||||
End point description |
Sputum samples were collected at all study visits for quantitative and qualitative culture for PA. Sputum PA density was quantified by logarithm transformation of the CFU value with base 10. Change from baseline in sputum PA density was calculated as the difference between the log10 CFU values at Day 28 (Visit 4) and the baseline value. Missing data was not imputed. Baseline log10 CFU and age group (<18 vs. >=18 years) were included as covariates in the analysis. Analysis based on ITT population (all participants who received at least part of one dose of AZLI or placebo). No imputation methods were used for the analysis.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 0 to Day 28
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Difference in change from baseline | ||||||||||||
Statistical analysis description |
Null hypothesis was there was no difference between 75 mg AZLI TID and placebo treatment groups in change from baseline in the log10 CFU at Day 28.
|
||||||||||||
Comparison groups |
Placebo v AZLI
|
||||||||||||
Number of subjects included in analysis |
68
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other [12] | ||||||||||||
P-value |
= 0.016 [13] | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
-1.21
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-2.2 | ||||||||||||
upper limit |
-0.23 | ||||||||||||
Notes [12] - Intergroup analysis of change from baseline. [13] - No adjustments were made for multiple comparisons. |
|
|||||||||||||
End point title |
Relative change from baseline in forced expiratory volume in 1 second (FEV1) percent predicted | ||||||||||||
End point description |
Spirometry was performed according to American Thoracic Society (ATS) guidelines at each visit. Treatment effect on the relative change from baseline in FEV1 percent predicted at Day 28 (Visit 4) was tested by the ANCOVA model using the ITT analysis set. Baseline FEV1 percent predicted and age group (<18 vs. >=18 years) were included as covariates in the analysis. Analysis based on ITT population (all participants who received at least part of one dose of AZLI or placebo). Missing baseline data were not imputed. Missing postbaseline data were imputed using worst-case value for participants who withdrew due to an AE or study drug intolerance. For all other missing data, LOCF method was used.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 0 to Day 28
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Difference in relative change from baseline | ||||||||||||
Statistical analysis description |
Null hypothesis was there was no difference between 75 mg AZLI TID and placebo treatment groups in % change from baseline in FEV1 % predicted at Day 28.
|
||||||||||||
Comparison groups |
Placebo v AZLI
|
||||||||||||
Number of subjects included in analysis |
157
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other [14] | ||||||||||||
P-value |
= 0.021 [15] | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
2.73
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.42 | ||||||||||||
upper limit |
5.04 | ||||||||||||
Notes [14] - Intergroup analysis of relative change from baseline. [15] - No adjustments were made for multiple comparisons. |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of participants testing positive for other respiratory pathogens | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
Sputum/throat swab samples were collected at all visits for quantitative and qualitative culture of Burkholderia species, Stenotrophomonas maltophilia, Achromobacter xylosidans, methicillin-resistant Staphylococcus aureus (MRSA), methicillin-sensitive S. aureus (MSSA), and Aspergillus species. One CFU on the culture from either a sputum or throat swab sample was considered presence of the particular organism. Analysis based on ITT population (all participants who received at least part of one dose of AZLI or placebo). No imputation methods were used for the analysis.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 0 to Day 28
|
|||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
The Minimum Concentrations of Aztreonam that Inhibit 50% and 90% of all PA Isolates (MIC50 and MIC90, respectively) | |||||||||||||||||||||
End point description |
Aztreonam susceptibility of PA isolates from expectorated sputum samples (collected at all visits) was assessed. The minimum inhibitory concentration (MIC) is the lowest concentration of antimicrobial agent that inhibits visible growth of a microorganism. The MIC50 and MIC90 for PA is the MIC required to inhibit the growth of 50% or 90% of PA isolates, respectively. Given that there might be multiple PA isolates for each participant, the MIC50 and MIC90 for PA was calculated using the MIC values for all PA isolates. The MIC50 and MIC90 were calculated by treatment group. Analysis based on ITT population (all participants who received at least part of one dose of AZLI or placebo).
Baseline and Day 28 MIC50 were ≤ 1 in the Placebo Group, and baseline MIC50 was ≤ 1 in the AZLI Group.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Day 0 to Day 28
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Treatment-emergent AEs were collected continuously from the first dose (Day 0) until 14 days after last AZLI/placebo dose (typically Day 42). Participants who discontinued were evaluated for at least 14 days after last dose of study drug.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
An AE was any physical/clinical worsening in symptoms/disease (including clinically significant change in lab values) experienced by participant at any time during study, whether or not event was considered related to study participation or study procedures. Participants were only counted once within a System Organ Class (SOC) and preferred term.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
11.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received placebo to match AZLI self administered 3 times daily (TID) for the duration of the study. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
AZLI
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received AZLI self administered 3 times daily for the duration of the study. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
There were no limitations affecting the analysis or results. |